Top Markets
#1 Black Phoenix Black Phoenix +354.79%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +76.58%
#4 Gold Park Gold Park +61.59%
#5 OpenEden OpenEden +47.95%
#6 Acurast Acurast +32.33%
#7 BasedHype BasedHype +27.12%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +20.48%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Alligator Bioscience AB (publ) Alligator Bioscience AB (publ)

Alligator Bioscience AB (publ)

ATORX
Classifica tra le azioni #40436
Alligator Bioscience AB (publ) is a research-intensive biotechnology company... Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Prezzo delle azioni
$0.00408798
Capitalizzazione di mercato
$147.44K
Variazione (1 giorno)
-0.54%
Variazione (1 anno)
-99.17%
Paese
SE
Scambia Alligator Bioscience AB (publ) (ATORX)

Categoria

Healthcare
EPS per Alligator Bioscience AB (publ) (ATORX)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Alligator Bioscience AB (publ), l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Alligator Bioscience AB (publ) da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE